{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"201","upperLimit":"490","value":"336"},{"groupId":"OG001","lowerLimit":"144","upperLimit":"429","value":"233"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"Time to subsequent antineoplastic therapy was defined as the time from randomization to the first date of subsequent antineoplastic therapy (excluding transplant). Participants without subsequent antineoplastic therapy were censored at the date of death or last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).","id":"OG000","title":"Alisertib"},{"description":"Pralatrexate 30 mg/m\\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).","id":"OG001","title":"Pralatrexate, or Romidepsin, or Gemcitabine"}],"paramType":"MEDIAN","populationDescription":"ITT population was defined as all participants who were randomized. The participants were analyzed according to the treatment they were randomized to receive, regardless of any errors of dosing.","reportingStatus":"POSTED","timeFrame":"From date of last study drug to date of subsequent antineoplastic therapy, if required; approximately 3 years","title":"Time to Subsequent Antineoplastic Therapy","type":"SECONDARY","unitOfMeasure":"days"}